**Basic purpose of the job** HEOR Manager or Senior Staff will be responsible for and lead the development and implementation of the evidence generation strategy to maximize Boehringer Ingelheim asset value and optimize access to medicines through product life cycle from early stage of clinical development to post-market. **Accountabilities** Develop HEOR generation strategy and efficiently implement relevant research targeting various stakeholders for optimizing access to Nippon Boehringer Ingelheim Co., Ltd products through the life cycle from the early pipeline stage of the clinical development to the post-launch, and achieve effective dissemination of evidence under complying with compliance. **Related performance indicators** 1. Develop the evidence generation strategy to maximize the asset values trough the collaboration with AT/eEL, and inputs local needs to corporate asset strategy and deliverables(AEP, IAP etc) 2.For responsible asset work on HEOR strategy discussions cross-functionally and lead the HEOR studies including RWE generation. 3.Have a responsibility for the whole process of evidence generation including study planning, medical writing, publication materials and dissemination of the results. Assess COAs including utility in clinical development, and validate or newly develop COA tools thorough the collaboration with corporate AT/corporate HEOR **Related performance indicators** 1. Lead the evaluation and study of COAs such as PRO/QOL tools in clinical trials. ２．Lead discussions on validation and new development of PRO/QOL tools and prepare the optimal PRO/QOL/utility instrument for maximizing product value and J-HTA evaluation. Plan and prepare for the Japanese HTA(J-HTA) system, and develop negotiation strategy with the authority **Related performance indicators** 1. Inputs local needs to global health economic model and relevant global deliverables 2. Lead local adaptation of a global model with local data generation, and responsible for J-HTA dossier preparation 3. Develop negotiation strategy and responsible for execution for its Understand related laws and guidelines and the trend of discussions in Japan and globally through the dialogues with HEOR/HTA experts, such as the data platform / drug price system / cost-effectiveness evaluation system and provide the latest situation into company/asset strategy appropriately’ **Related performance indicators** ・Conduct the opportunity/risk assessment of the impact of current/future trends of regulation and guideline related HEOR/HTA on the pharmaceutical industry and Boehringer Ingelheim Japan. ・Build relationship with the experts in HEOR/HTA **Regulatory and / or Organisational Requirements** •The following knowledge is required for job performance. ・ Epidemiology ・ Biostatistics ・ Health economics ・ Design and evaluation of observational studies ・ PRO / QOL evaluation ・ Medical insurance system, drug price system, J-HTA ・ Medical insurance system and healthcare technology evaluation system in other countries **Job Complexity** Appropriately and timely grasp changes in the external environment related to HEOR, such as the HTA system and RWE in both of Japan and overseas. Predict the impact on the pharmaceutical industry and companies and develop and implement strategies. Take charge of the whole process of HEOR-related evidence generation activities including evidence generation strategy, implementation of the analysis, medical writing, publication, in collaboration with relevant internal x-functional team 3. Responds promptly to other internal and external requirements and issues with flexibility. **Interfaces** Boehringer Ingelheim:Corporate HEOR, Global Market Access Nippon Boehringer Ingelheim Co., Ltd: MKT, Medicine(TA, CD, PM, Epi, BDS),Market Access Pricing, PE,CMO... External stakeholders: MHLW, Core2Health, Academia, Vendor, Industry associations(JPMA, EFPIA) **Job Expertise** ・HEOR and RWE related activities including health economic evaluation, outcomes research, evidence strategy planning, analysis, medical writing, publication ・Strategy development and project management/lead of cross-functional projects ・Scientific discussions with external medical experts, health economics experts, and RWE experts **Job Impact** Maximize patient access to BI assets by implementing evidence generation strategy aiming at maximization of asset value and optimization of market access, and minimization of the risk of post-launch price adjustments under the HTA system. Contribute greatly to the realization of sustainable NBI business. **Minimum Education/Degree Requirements** Master or PhD in public health (epidemiology, clinical epidemiology, pharmacoepidemiology, PRO / QOL, qualitative research, etc.), or pharmacoeconomics or health economics **Required Capabilities (Skills, Experience, Competencies)** Knowledge of epidemiology ・ Knowledge of biostatistics ・ Knowledge of health economics ・ Knowledge of observational studies ・ Experience in health economic evaluation model, observational research and PRO / QOL research (until publication) ・ Capability or experiences of development of HEOR/RWE strategy ・ Expertise and capability to have scientific discussions with external medical experts and health economic experts ・ Interpersonal skills that enable smooth and productive relationships with internal and external stakeholders ・ Knowledge of Japanese medical insurance system, drug price system, HTA system ・ Knowledge of medical insurance systems and medical technology evaluation systems in other countries ・ Skills to carry out work in English on a daily basis Recruiter : K Nagai All qualified applicants will receive consideration for employment without regard to a person’s actual or perceived race, including natural hairstyles, hair texture and protective hairstyles; color; creed; religion; national origin; age; ancestry; citizenship status, marital status; gender, gender identity or expression; sexual orientation, mental, physical or intellectual disability, veteran status; pregnancy, childbirth or related medical condition; genetic information (including the refusal to submit to genetic testing) or any other class or characteristic protected by applicable law.